Prognostic significance of Id-1 and its association with EGFR in renal cell cancer

Histopathology

Volumn 50, Issue 4, 2007, Pages 484-490

  Li, X ^a,b   Zhang, ^a,b   Xin, D ^b   Chua, C W ^a   Wong, Y C ^a   Leung, S C L ^a   Na, Y ^b   Wang, X ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b PEKING UNIVERSITY   (China)

Author keywords

EGFR; Id 1; Immunohistochemistry; Microarray; Renal cell cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; INHIBITOR OF DIFFERENTIATION 1;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STAINING; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF DIFFERENTIATION PROTEIN 1; KIDNEY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REFERENCE VALUES; TISSUE ARRAY ANALYSIS;

EID: 33847289707     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2007.02637.x     Document Type: Article

References (32)

1. Vogelzang NJ, Stadler WM. Kidney cancer. Lancet 1998; 352; 1691-1696.
2. McLaughlin JK, Lipworth L. Epidemiologic aspects of renal cell cancer. Semin. Oncol. 2000; 27; 115-123.
3. Henriksson R, Nilsson S, Colleen S et al. Survival in renal cell carcinoma - a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen. Br. J. Cancer 1998; 77; 1311-1317.
4. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J. Urol. 2000; 163; 408-417.
5. Radinsky R, Risin S, Fan D et al. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin. Cancer Res. 1995; 1; 19-31.
6. Rowinsky EK, Schwartz GH, Gollob JA et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J. Clin. Oncol. 2004; 22; 3003-3015.
7. Itakura Y, Sasano H, Shiga C et al. Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 1994; 74; 795-804.
8. Ljungberg B, Gafvels M, Damber JE. Epidermal growth factor receptor gene expression and binding capacity in renal cell carcinoma, in relation to tumor stage, grade and DNA ploidy. Urol. Res. 1994; 22; 305-308.
9. Yoshida K, Tosaka A, Takeuchi S, Kobayashi N. Epidermal growth factor receptor content in human renal cell carcinomas. Cancer 1994; 73; 1913-1918.
10. Sargent ER, Gomella LG, Belldegrun A, Linehan WM, Kasid A. Epidermal growth factor receptor gene expression in normal human kidney and renal cell carcinoma. J. Urol. 1989; 142; 1364-1368.
11. Petrides PE, Bock S, Bovens J, Hofmann R, Jakse G. Modulation of pro-epidermal growth factor, pro-transforming growth factor alpha and epidermal growth factor receptor gene expression in human renal carcinomas. Cancer Res. 1990; 50; 3934-3939.
12. Mydlo JH, Michaeli J, Cordon-Cardo C et al. Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue. Cancer Res. 1989; 49; 3407-3411.
13. Yao M, Shuin T, Misaki H, Kubota Y. Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer. Cancer Res. 1988; 48; 6753-6757.
14. Dawson NA, Guo C, Zak R et al. A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clin. Cancer Res. 2004; 10; 7812-7819.
15. Motzer RJ, Amato R, Todd M et al. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest. New Drugs 2003; 21; 99-101.
16. Ling MT, Wang X, Lee DT et al. Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R). Carcinogenesis 2004; 25; 517-525.
17. Benezra R, Davis RL, Lockshon D, Turner DL, Weintraub H. The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell 1990; 61; 49-59.
18. Lin CQ, Singh J, Murata K et al. A role for Id-1 in the aggressive phenotype and steroid hormone response of human breast cancer cells. Cancer Res. 2000; 60; 1332-1340.
19. Maruyama H, Kleeff J, Wildi S et al. Id-1 and Id-2 are overexpressed in pancreatic cancer and in dysplastic lesions in chronic pancreatitis. Am. J. Pathol. 1999; 155; 815-822.
20. Schindl M, Oberhuber G, Obermair A et al. Overexpression of Id-1 protein is a marker for unfavorable prognosis in early-stage cervical cancer. Cancer Res. 2001; 61; 5703-5706.
21. Ouyang XS, Wang X, Lee DT, Tsao SW, Wong YC. Over expression of ID-1 in prostate cancer. J. Urol. 2002; 167; 2598-2602.
22. Schindl M, Schoppmann SF, Strobel T et al. Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors. Clin. Cancer Res. 2003; 9; 779-785.
23. Fong S, Itahana Y, Sumida T et al. Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis. Proc. Natl Acad. Sci. USA 2003; 100; 13543-13548.
24. Ling MT, Wang X, Ouyang XS et al. Activation of MAPK signaling pathway is essential for Id-1 induced serum independent prostate cancer cell growth. Oncogene 2002; 21; 8498-8505.
25. Ouyang XS, Wang X, Ling MT et al. Id-1 stimulates serum independent prostate cancer cell proliferation through inactivation of p16 (INK4a)/pRB pathway. Carcinogenesis 2002; 23; 721-725.
26. Zhang X, Ling MT, Feng H et al. Id-I stimulates cell proliferation through activation of EGFR in ovarian cancer cells. Br. J. Cancer 2004; 91; 2042-2047.
27. Sobin LH, Fleming ID. TNM classification of malignant tumors, 5th edn. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997; 80; 1803-1804.
28. Skinner DG, Colvin RB, Vermillion CD, Pfister RC, Leadbetter WF. Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer 1971; 28; 1165-1177.
29. Kovacs G, Akhtar M, Beckwith BJ et al. The Heidelberg classification of renal cell tumours. J. Pathol. 1997; 183; 131-133.
30. Kononen J, Bubendorf L, Kallioniemi A et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 1998; 4; 844-847.
31. Minn AJ, Gupta GP, Siegel PM et al. Genes that mediate breast cancer metastasis to lung. Nature 2005; 436; 518-524.
32. Ling MT, Lau TC, Zhou C et al. Overexpression of Id-1 in prostate cancer cells promotes angiogenesis through the activation of vascular endothelial growth factor (VEGF). Carcinogenesis 2005; 26; 1668-1676.